propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
Published 2 years ago • 774 plays • Length 3:07Download video MP4
Download video MP3
Similar videos
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
0:39
stereotactic body rt in patients with oligometastatic crpc undergoing 1l treatment with abiraterone
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
1:27
hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
5:36
propel trial
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
2:34
first-line treatments for patients with mhspc and mcrpc
-
1:39
challenges in the field of parpi treatment for mcrpc
-
3:14
treatment with abiraterone acetate without steroids in mcrpc
-
1:34
combination therapies for the treatment of prostate cancer
-
1:17
abiraterone for the treatment of cn1 prostate cancer
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations